MAPK3

Across TCGA pan-cancer cohorts, MAPK3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAPK3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAPK3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAPK3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where MAPK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.977	0.322	.003	18	view →
LUAD	DFS	Tertile	All	1.000	0.603	.007	12	view →
CCRCC	DFS	Median	III,IV	0.860	0.515	.006	8	view →
UCEC	DFS	Median	II,III,IV	0.533	0.882	.035	4	view →
HNSC	OS	Median	All	0.889	0.822	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAPK3–PDAC (OS)

Open the PDAC breakdown →